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Introduction: Isoniazid (INH) is an essential drug for 
tuberculosis (TB) treatment. Resistance to INH may 
increase the likelihood of negative treatment out-
come. Aim: We aimed to determine the impact of INH 
mono-resistance on TB treatment outcome in the 
European Union/European Economic Area and to iden-
tify risk factors for unsuccessful outcome in cases 
with INH mono-resistant TB. Methods: In this obser-
vational study, we retrospectively analysed TB cases 
that were diagnosed in 2002–14 and included in the 
European Surveillance System (TESSy). Multilevel 
logistic regression models were applied to identify 
risk factors and correct for clustering of cases within 
countries. Results: A total of 187,370 susceptible and 
7,578 INH mono-resistant TB cases from 24 countries 
were included in the outcome analysis. Treatment was 
successful in 74.0% of INH mono-resistant and 77.4% 
of susceptible TB cases. In the final model, treatment 
success was lower among INH mono-resistant cases 
(Odds ratio (OR): 0.7; 95% confidence interval (CI): 
0.6–0.9; adjusted absolute difference in treatment 
success: 5.3%). Among INH mono-resistant TB cases, 
unsuccessful treatment outcome was associated with 
age above median (OR: 1.3; 95% CI: 1.2–1.5), male sex 
(OR: 1.3; 95% CI: 1.1–1.4), positive smear microscopy 
(OR: 1.3; 95% CI: 1.1–1.4), positive HIV status (OR: 3.3; 
95% CI: 1.6–6.5) and a prior TB history (OR: 1.8; 95% 
CI: 1.5–2.2). Conclusions: This study provides evidence 
for an association between INH mono-resistance and 
a lower likelihood of TB treatment success. Increased 
attention should be paid to timely detection and man-
agement of INH mono-resistant TB.
Introduction
Tuberculosis (TB) causes a large degree of suffering 
and an estimated 1.3 million deaths per year glob-
ally, occurring mainly in less affluent countries, but 
also in upper-middle and high-income countries in the 
European Union/European Economic Area (EU/EEA) 
[1,2]. In Europe, there has been a steady decline in TB 
notification rates of ca 5% per year. Nevertheless, TB 
remains a considerable problem because of multidrug-
resistant (MDR) and extensively drug-resistant (XDR) 
TB [3].
The main public health response to the TB epidemic 
consists of early diagnosis, prevention of transmission 
and adequate treatment. In general, treatment is most 
successful when there is no resistance to any of the 
drugs designated for treatment of TB [4], and the drugs 
isoniazid (INH) and rifampicin (RIF) can be included in 
the treatment regimen. INH has long been an essential 
component of first-line treatment for active TB and an 
important drug in TB control because of its potent early 
bactericidal activity, low rate of adverse events and low 
cost [5]. Currently, there is no equivalent alternative 
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available [6]. Resistance to INH is prevalent [4], with 
substantial geographic variation [7].
INH mono-resistance increases the likelihood of nega-
tive treatment outcome and progression to MDR TB 
[4,8,9]. Reported treatment outcome seems to differ by 
setting and region for cases with INH-resistant TB [10-
12]. Population groups that are especially at risk of nega-
tive treatment outcome due to INH mono-resistance are 
children and HIV-positive patients [13-15]. Recently, two 
systematic reviews assessed treatment options for INH 
mono-resistant TB [8,16]. One review concluded that 
treatment with first-line drugs resulted in suboptimal 
outcome [8], whereas the other showed that extending 
the duration of RIF and increasing the number of effec-
tive drugs lowered the odds of unfavourable outcome 
[16]. An analysis of individual patient data conducted 
in the framework of a World Health Organization (WHO) 
guideline development process showed that the addi-
tion of a fluoroquinolone to a regimen of 6 months of 
daily RIF, ethambutol (EMB) and pyrazinamide (PZA) 
was associated with improved treatment success in 
INH-resistant cases [17]. After an evaluation of all avail-
able evidence, WHO has issued new guidelines on 
treatment for patients with INH mono-resistance [18]. 
Discussion is ongoing as to whether to maintain INH in 
the treatment regimen if a low degree of resistance is 
detected; however, there is limited data on the effect 
this strategy has on treatment outcome.
The European Surveillance System (TESSy), hosted 
by the European Centre for Disease Prevention and 
Control (ECDC), contains case-based information for 
more than 1.5 million TB cases reported by EU/EEA 
countries between 1995–2015 [3]. In contrast to the 
information from randomised controlled trials (RCTs) 
and cohort studies that were included in the system-
atic reviews, TESSy includes information on treatment 
outcome obtained in a programmatic setting [8,16]. 
These data are from a larger number of patients, are 
more recent and are more EU/EEA-focused than the 
data in the aforementioned reviews. We therefore set 
out to analyse this dataset to determine the current 
treatment outcome of INH mono-resistant TB in the EU/
EEA and to identify risk factors for unsuccessful treat-
ment outcome in cases with INH mono-resistance.
Methods
Study population and data sources
In this observational study, we retrospectively ana-
lysed TB notification data reported to the TESSy data-
base between 2002–14. We included pulmonary and 
extra-pulmonary TB cases with available information 
on treatment outcome and drug-susceptibility testing 
(DST) results for at least INH, RIF, streptomycin (STR) 
and EMB. Information on DST for PZA was not collected 
in TESSy during the study period and therefore PZA 
was not part of our inclusion criteria.
Operational definitions
Treatment outcome was reported 12, 24 and 36 months 
after the start of TB treatment. We categorised treat-
ment outcome in accordance with the 2017 joint WHO 
Regional Office for Europe/ECDC surveillance and mon-
itoring report [3]. For cases with a treatment outcome 
of ‘still on treatment’ at 12 or 24 months, the final 
treatment outcome reported at 24 or 36 months was 
used, respectively. Unadjusted data was stratified by 
age, although this stratification was not described in 
the protocol for this study. The operational definitions 
used in this study are listed in the Box.
Statistical analysis and modelling approach
To investigate the impact of INH mono-resistant TB 
compared with fully drug-susceptible TB on treatment 
success, we applied a multilevel logistic regression 
model. To adjust for the heterogeneity between coun-
tries, the model was corrected with a random intercept 
at the country level for the differences in the average 
treatment success rate between countries and with 
a random slope for the differences in the INH mono-
resistance effect on the treatment success rate at the 
country level. The necessity of adding a random inter-
cept and a random slope in the model was determined 
using the likelihood-ratio test. The main outcome was 
dichotomised as unsuccessful treatment (failed, died, 
lost to follow-up and not evaluated) vs treatment suc-
cess (cured or completed), using the final reported 
treatment outcome. Independent variables available 
in the TESSy data (age, sex, geographical origin, type 
of TB, microscopic confirmation, history of TB, HIV sta-
tus and reporting year) were also assessed as possible 
Box 
Operational definitions for analysis of European 
tuberculosis surveillance data, 2002–2014 
The following definitions were used:
• INH mono-resistant TB cases: cases with resistance to 
INH and documented susceptibility to RIF, STR and EMB;
• Cases with fully drug-susceptible TB: cases with 
documented susceptibility to INH, RIF, STR and EMB;
• New TB cases: cases who were never previously treated 
for TB or who received drug treatment for less than 1 
month;
• Cases with a history of TB: cases who were previously 
treated for TB for 1 month or more (for countries who did 
not report information about previous treatment, the 
variable previous diagnosis was used as a proxy);
• Geographical origin of cases, i.e. native vs foreign: 
based on the country of birth or, if this information was 
unavailable, on the citizenship of the patient;
• Low TB-incidence country: country with a TB incidence 
rate < 10 cases per 100,000 population [31];
• High TB-incidence country: country with a TB incidence 
rate ≥ 10 cases per 100,000 population [31].




Flow chart of cases included in analysis of treatment outcome of isoniazid mono-resistant tuberculosis, 31 EU/EEA 
countries, 2002–2014
1,008,818 TB cases reported to 
TESSy between 2002 and 2014 
844,193 TB cases with information 
on treatment outcome  
164,625 TB cases from 
countries that do not report 
treatment outcomes 
618,291 TB cases without 
information on DST for INH, 
RIF, EMB or STR 
221,871 ante-mortem TB cases with 
information on treatment outcome 
and DST for at least INH, RIF, EMB 
and STR 
 





12,270 MDR-TB cases 




resistant TB cases 
809 RIF mono-resistant TB cases 
401 EMB mono-resistant TB cases 
6,569 STR mono-resistant TB cases 
4,031 TB cases diagnosed 
after death (post-mortem) 
840,162 ante-mortem TB cases with 
information on treatment outcome  
 
DST: drug-susceptibility testing; EMB: ethambutol; EU/EEA: European Union/European Economic Area; INH: isoniazid; MDR-TB: multidrug-
resistant TB; RIF: rifampicin; STR: streptomycin; TB: tuberculosis; TESSy: the European Surveillance System; WHO: World Health 
Organization.
a According to WHO, poly-resistance in TB cases refers to resistance to two or more first-line drugs, but not to both isoniazid and rifampicin, 




Characteristics of tuberculosis cases, by excluded and included cases, 31 EU/EEA countries, 2002–2014 (n = 1,008,818)
Characteristics
Excluded TB cases Included TB cases
p valuea
n % n %
Total 813,870 80.7 194,948 19.3 –
Median age in years (IQR) 43 (30–58) NA 45 (32–60) NA 0.05
Male sex 522,843 64.3 127,642 65.5 0.91
Cases of foreign origin 172,776 22.4 56,451 29.3 0.51
Extra-pulmonary TB 177,592 21.9 28,032 14.4 0.11
New TB cases 638,026 78.4 163,546 83.9 0.02
Microscopic confirmation 296,127 48.3 93,560 61.2 < 0.01
Positive HIV status 4,976 0.6 1,248 0.6 0.68
Proportion of cases by reporting countries
Austria 4,771 44.6 5,919 55.4
p < 0.01
Belgiumb 13,830 100 0 0
Bulgaria 14,542 71.9 5,695 28.1
Croatia 619 38.9 972 61.1
Cyprus 328 57.3 244 42.7
Czech Republic 4,927 46.4 5,704 53.7
Denmark 4,086 82.9 843 17.1
Estonia 2,927 50.9 2,826 49.1
Finland 2,577 58.7 1,817 41.3
Francec 70,140 100 0 0
Germany 28,524 41.6 40,015 58.4
Greeced 7,911 100 0 0
Hungary 17,720 78.4 4,879 21.6
Iceland 137 97.8 3 2.2
Ireland 3,660 67.0 1,803 33.0
Italyc 56,146 100 0 0
Latvia 7,533 47.8 8,209 52.2
Liechtensteind 5 100 0 0
Lithuania 13,572 51.9 12,570 48.1
Luxembourgd 443 100 0 0
Malta 305 68.9 138 31.2
Netherlands 8,314 59.0 5,769 41.0
Norway 1,450 34.4 2,771 65.6
Poland 70,917 64.3 39,430 35.7
Portugal 24,906 60.5 16,241 39.5
Romania 311,991 98.9 3,265 1.1
Slovenia 432 15.4 2,372 84.6
Slovakia 4,189 52.6 3,783 47.4
Spainc 54,232 100 0 0
Sweden 5,881 82.3 1,264 17.7
UK 76,855 73.0 28,416 27.0
EU/EEA: European Union/European Economic Area; HIV: human immunodeficiency virus; IQR: interquartile range; TB: tuberculosis; TESSy: The 
European Surveillance System; UK: United Kingdom.
a Obtained by a multivariable logistic regression model corrected for clustering within countries.
b Not performing drug susceptibility testing for streptomycin.
c Not reporting case-based drug susceptibility data and treatment outcome data.










n % n %
Total 187,370 NA 7,578 NA
Sex
Female 64,640 34.5 2,566 33.8
Male 122,636 65.4 5,006 66.1
Unknown 94 0.1 6 0.1
Age (years)
Median (IQR) 46 (32–60) NA 41 (30–54) NA
Age group
< 15 3,160 1.7 174 2.3
15–44 89,845 47.9 4,346 57.3
45–64 57,172 30.5 2,202 29.0
> 64 37,127 19.8 855 11.3
Unknown 66 0.1 1 0.1
Geographical origin
Native 131,344 70.1 4,639 61.2
Foreign 53,648 28.6 2,803 37.0
Unknown 2,378 1.3 136 1.8
Type of TB
Pulmonary 160,231 85.5 6,341 83.7
Extra-pulmonary 26,813 14.3 1,219 16.1
Unknown 326 0.2 18 0.2
Sputum smear microscopy
Negative 57,063 30.4 2,183 28.8
Positive 89,898 47.9 3,662 48.3
Unknown 40,409 21.7 1,733 22.9
History of TB
New TB case 157,526 84.1 6,020 79.4
Case with history of TB 17,634 9.4 1,027 13.6
Case with unknown TB history 12,210 6.5 531 7.0
HIV status
Negative 17,624 9.4 823 10.9
Positive 1,203 0.6 45 0.6
Unknown 168,543 90.0 6,710 88.5
EU/EEA countries
Low TB incidence 74,742 40.0 2,582 34.1
High TB incidenceb 112,628 60.0 4,996 65.9
Reporting years
2002–2005 49,532 26.4 2,089 27.6
2006–2009 61,478 32.8 2,403 31.8
2010–2014 76,360 40.8 3,086 40.6
EU/EEA: European Union/European Economic Area; INH: isoniazid; IQR: interquartile range; NA: not applicable; TB: tuberculosis; TESSy: The 
European Surveillance System; UK: United Kingdom.
a TB cases susceptible to at least isoniazid, rifampicin, ethambutol and streptomycin.
b High-incidence countries were defined as those with 10 or more TB cases per 100,000 population in 2015 (Bulgaria, Croatia, Estonia, Latvia, 
Lithuania, Poland, Portugal, Romania and the UK).
Data source: TESSy.
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confounders in the relationship between INH mono-
resistant TB and treatment success. Independent varia-
bles that caused a change in the regression coefficient 
between INH mono-resistant TB and treatment suc-
cess of > 10% were considered potential confounders 
and were retained in the final multilevel multivariable 
model. In addition, we evaluated the interaction of INH 
mono-resistant TB with age and history of TB on treat-
ment success at a p value of 0.1. Furthermore, a sen-
sitivity analysis was conducted to assess the impact 
of INH mono-resistance after excluding cases with the 
outcome ‘not evaluated’.
To identify risk factors for an unsuccessful treatment 
outcome in INH mono-resistant cases, the multilevel 
univariate and multivariable logistic regression models 
were used to examine the association between predict-
ing variables (age, sex, geographical origin, microscopy 
confirmation, history of TB, HIV status, type of TB and 
reporting year) and unsuccessful treatment outcome. 








n % n %
Number of TB cases by reporting countryb
Austria 5,716 96.6 203 3.4
Bulgaria 5,416 95.1 279 4.9
Croatia 953 98.0 19 2.0
Cyprus 224 91.8 20 8.2
Czech Republic 5,626 98.6 78 1.4
Denmark 807 95.7 36 4.3
Estonia 2,721 96.3 105 3.7
Finland 1,759 96.8 58 3.2
Germany 38,700 96.7 1,315 3.3
Hungary 4,663 95.6 216 4.4
Iceland 1 33.3 2 66.7
Ireland 1,725 95.7 78 4.3
Latvia 7,648 93.1 561 7.4
Lithuania 11,790 93.8 780 6.2
Malta 136 98.5 2 1.5
Netherlands 5,508 95.5 261 4.5
Norway 2,630 94.9 141 5.1
Poland 38,579 97.8 851 2.2
Portugal 15,764 97.1 477 2.9
Romania 3,032 92.9 233 7.1
Slovenia 2,346 98.9 26 1.1
Slovakia 3,697 97.7 86 2.3
Sweden 1,204 95.3 60 4.7
UK 26,725 94.1 1,691 5.6
Final treatment outcome
Treatment success 144,961 77.4 5,611 74.0
Death 14,681 7.8 516 6.8
Failed 1,111 0.6 102 1.4
Lost to follow-up 10,259 5.5 567 7.5
Not evaluated 16,358 8.7 782 10.3
EU/EEA: European Union/European Economic Area; INH: isoniazid; TB: tuberculosis; TESSy: The European Surveillance System; UK: United 
Kingdom.
a TB cases susceptible to at least isoniazid, rifampicin, ethambutol and streptomycin.
b Seven countries (Belgium, France, Greece, Italy, Liechtenstein, Luxembourg and Spain) were excluded from this study, as they did not report 
treatment outcome and/or the required susceptibility data.
Data source: TESSy.
Table 2b
Characteristics of tuberculosis cases by isoniazid mono-resistance status, 24 EU/EEA countries, 2002–2014 (n = 194,948)
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the included study population. In a sensitivity analysis, 
cases with the outcome ‘not evaluated’ were excluded. 
As the outcomes were proportions, we used logistic 
regression for all models. Odds ratios (OR) with 95% 
confidence intervals (CI) were calculated to assess 
the strength of the association. All analyses were per-
formed using the STATA (Stata/SE 14.1, StataCorp LP, 
Texas, United States (US)) software.
Ethical statement
This study is based on data collected on the basis 
of statutory notification in each EU/EEA country and 
reported anonymously to ECDC on the basis of decision 
No 2119/98/EC of the European Parliament and of the 
Council [19]. Therefore, informed consent from patients 
is not required.
Results
Characteristics of the study population
From 2002–14, a total of 1,008,818 TB cases were noti-
fied in 31 EU/EEA countries and reported to TESSy. TB 
cases without reported treatment outcome for the years 
2002–14 (n = 164,625) or who were diagnosed post-
mortem (n = 4,031) were excluded from our analysis. We 
also excluded 618,291 TB cases without DST results for 
INH, RIF, EMB or STR. Furthermore, we excluded cases 
with drug resistance other than INH mono-resistance 
(n = 26,923). The remaining 194,948 TB cases from 24 
Figure 2
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Fully susceptible TB INH mono-resistant TB
B. Final reported treatment outcome
Lost to follow-up
EU/EEA: European Union/European Economic Area; INH: isoniazid; TESSy: The European Surveillance System.
a Treatment outcome at 12 months.
b Final reported treatment outcome.
Data source: TESSy.
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EU/EEA countries fulfilled the inclusion criteria and 
were therefore eligible for our analysis. Of them, 7,578 
(3.9%) were cases with INH mono-resistant TB (Figure 
1). Differences in the characteristics of included and 
excluded cases are presented in Table 1. No change in 
the proportion of INH mono-resistant TB was observed 
during the study period (Trend analyses: p value = 0.30).
The majority of included cases were reported by 
Germany, Poland and the United Kingdom (UK) (20.5%, 
20.2% and 14.6%, respectively). Cases with INH mono-
resistant TB were more likely to be younger than cases 
with fully drug-susceptible TB (median age 41 vs 46 
years), be of foreign origin (37.0% vs 28.6%) and have 
a prior history of TB (13.6% vs 9.4%). Cases with INH 
mono-resistant TB were also more frequently reported 
by high TB-incidence countries, compared with low 
TB-incidence countries (65.9% vs 60.0%) (Table 2).
Tuberculosis treatment outcome
At 12 months after the start of treatment, INH mono-
resistant TB cases had a lower TB treatment suc-
cess rate than cases with fully susceptible TB (67.7% 
(5,131/7,578) vs 75.8% (142,051/187,370)). Noticeably, 
a higher proportion of cases ‘still on treatment’ was 
observed among INH mono-resistant TB cases in com-
parison to fully susceptible TB cases (9.8% (745/7,578) 
vs 3.0% (5,651/187,370), respectively). The treatment 
success rate was still lower in INH mono-resistant 
TB cases compared with fully susceptible TB cases 
(74.0% vs 77.4%), when assessing the final reported 
treatment outcome (Table 2). Fewer INH mono-resist-
ant cases died while being treated for TB, compared 
with fully susceptible TB cases (6.8% vs 7.8%) (Table 
2). However, a higher proportion of cases with treat-
ment failure was observed among INH mono-resistant 
TB cases in comparison to fully susceptible TB cases 
(1.4% vs 0.6%, respectively) (Table 2). Unknown treat-
ment outcome (i.e. lost to follow-up and not evaluated) 
was documented for 17.8% of INH mono-resistant TB 
cases vs 14.2% of fully susceptible TB cases (Table 
2, Figure 2).
For cases younger than the median age of 45 years, the 
final treatment success rates were 76.6% (3,341/4,362) 
for INH mono-resistant TB and 82.6% (73,960/89,536) 
for susceptible TB. For cases aged ≥ 45 years, the 
treatment success rate decreased for both case 
groups; however, the difference was smaller (70.6% 
(2,270/3,216) for INH mono-resistant TB vs 72.6% 
(71,001/97,834) for fully susceptible TB). Treatment 
outcome by age group and INH mono-resistance sta-
tus are presented in Figure 3a. The treatment success 
rate varied between countries for both fully suscepti-
ble and INH mono-resistant TB cases. Markedly, a rela-
tively high proportion of deaths during TB treatment 
was reported among INH mono-resistant TB cases in 
Croatia (21.1%) and Slovenia (19.2%). In Romania and 
Hungary, a high proportion of cases with treatment 
failure was observed (12.0% and 10.2%, respectively) 
(Figure 3b).
Impact of INH mono-resistance on tuberculosis 
treatment success
In the univariate model corrected for clustering within 
countries, INH mono-resistance was associated with a 
lower TB treatment success compared with cases with 
fully susceptible TB (OR: 0.8; 95% CI: 0.7–0.9). Out of 
all statistically evaluated covariates, adding age, micro-
scopic confirmation or history of TB to the crude model 
led to the predefined change (> 10%) in the regression 
coefficient for INH mono-resistance and, therefore, 
these covariates were retained in the multivariable 
model as potential confounders. No interactions of INH 
mono-resistant TB with age (p value = 0.9) or history of 
TB treatment (p value = 0.2) were observed; therefore, 
these variables were not included in the final model.
In the final multivariable model, treatment success 
among INH mono-resistant TB was lower compared 
with fully drug-susceptible TB (adjusted OR: 0.7; 95% 
CI: 0.6–0.9). This corresponds to an adjusted treat-
ment success of 74.0% for INH mono-resistant TB and 
79.3% for fully susceptible TB, adjusted absolute differ-
ence of 5.3% (Supplementary Table S1). The treatment 
success remained lower among INH mono-resistant TB 
compared with fully susceptible TB in the multivari-
able model after excluding cases with ‘not evaluated’ 
as treatment outcome (OR: 0.7; 95% CI: 0.6–0.8) (data 
not shown).
Factors associated with unsuccessful final 
treatment outcome of INH mono-resistant 
tuberculosis cases
In the multivariable model adjusted for heterogene-
ity between countries, unsuccessful treatment among 
INH mono-resistant TB cases was associated with 
age ≥ median age (41 years) (OR: 1.3; 95% CI: 1.2–1.5), 
male sex (OR: 1.3 95%; CI: 1.1–1.4), positive microscopy 
(OR: 1.3; 95% CI: 1.1–1.4), history of TB (OR: 1.8; 95% 
CI: 1.5–2.2) and positive HIV status (OR: 3.3; 95% CI: 
1.6–6.5) (Figure 4) (Supplementary Table S2). In the 
sensitivity analysis, excluding cases with the treatment 
outcome ‘not evaluated’, no change in the associated 
risk factors was observed (data not shown).
INH mono-resistant and fully susceptible TB shared the 
same risk factors for unsuccessful treatment, except 
for being of foreign origin, which was associated with a 
higher risk for unsuccessful treatment in fully suscep-
tible but not INH mono-resistant TB cases in the multi-
variable model (data not shown).
Discussion
Our retrospective study of European surveillance data, 
including 7,578 cases of INH mono-resistant TB and 
187,370 cases of fully susceptible TB, shows that INH 
mono-resistance is associated with lower TB treat-
ment success in the final TB treatment outcome. This 
association between INH mono-resistance and lower 
treatment success is in line with a previous system-
atic review [20]. Although this review was published 
in 2009, it includes many studies that were published 
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Figure 3
Treatment outcome of tuberculosis by isoniazid mono-resistance status and (A) age groupa and (B) reporting country, 24 
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Croatia (N = 953)
Cyprus (N = 224)
Finland (N = 1,759)
Ireland (N = 1,725)
Hungary (N = 4,663)
Poland (N = 38,579)
Germany (N = 38,700)
Czech Republic (N = 5,626)
Austria (N = 5,716)
Lithuania (N = 11,790)
Malta (N = 136)
UK (N = 26,725)
Estonia (N = 2,721)
Slovenia (N = 3,697)
Denmark (N = 807)
Sweden (N = 1,204)
Romania (N = 3,032)
Bulgaria (N = 5,416)
Slovakia (N = 2,346)
Latvia (N = 7,648)
Netherlands (N = 5,508)
Portugal (N = 15,764)
Norway (N = 2,630)
Iceland (N = 1)
Cyprus (N = 20)
Finland (N = 58)
Malta (N = 2)
Croatia (N = 19)
Ireland (N = 78)
Estonia (N = 105)
Poland (N = 851)
UK (N = 1,691)
Hungary (N = 216)
Slovenia (N = 26)
Romania (N = 233)
Germany (N = 1,315)
Czech Republic (N = 78)
Lithuania (N = 780)
Austria (N = 203)
Bulgaria (N = 279)
Sweden (N = 60)
Denmark (N = 36)
Latvia (N = 561)
Portugal (N = 477)
Slovakia (N = 86)
Netherlands (N = 261)
Norway (N = 141)
Iceland (N = 2)
Fully susceptible TB INH mono-resistant TB
Success Death Failed
Lost to follow-up Not evaluated
Proportion of cases (%) Proportion of cases (%)
B.
EU/EEA: European Union/European Economic Area; INH: isoniazid; TB: tuberculosis; TESSy: the European Surveillance System; TS: treatment 
success; UK: United Kingdom.
a Information missing for 67 cases.
Data source: TESSy.
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before the year 2000 and were mainly conducted in 
countries in Asia and Africa. The same applies to the 
reviews evaluating treatment regimens for INH mono-
resistant TB that were published in 2016 [16] and 2017 
[8], respectively. Therefore, our analysis of more recent 
2002–14 EU/EEA surveillance data represents an addi-
tion to the currently available evidence.
Studies of TB treatment outcome under routine pro-
grammatic conditions have shown inconsistent results 
regarding treatment outcome of INH mono-resistant 
TB. While studies from the US [10], Denmark [12] and 
Israel [21] reported treatment outcome for INH mono-
resistant TB as excellent, highly successful or similar 
to drug-susceptible TB, studies from Peru [22], Mexico 
[23], Georgia [24] and South Africa [11] showed poorer 
treatment outcome compared with fully susceptible 
TB. Possible explanations might be differences in the 
included patient populations; for example, regarding 
HIV prevalence [11,12], the availability of resources for 
patients, the accessibility of healthcare systems or the 
use of different treatment regimens. Our study, which 
pools data from 24 low HIV-prevalence and predomi-
nantly high-income European countries, shows that 
INH mono-resistance negatively affects treatment out-
come. The study findings also highlight the need for 
timely identification of patients with INH mono-resist-
ant TB, especially as rapid testing in recent years has 
focused more on the detection of RIF resistance as a 
proxy for MDR TB [6].
Figure 4
Factors associated with unsuccessful treatment among cases with isoniazid mono-resistant tuberculosis, EU/EEA, 2002–










Case with history of TB









 Country of origin
Microscopic confirmation
 Previous TB treatment
 Type of TB
 HIV status
 Reporting year
100.2 1 2 50.5
Odds ratio (log scale)
Univariable
Multivariable
CI: confidence interval; EU/EEA: European Union/European Economic Area; INH: Isoniazid; TB: tuberculosis; TESSy: the European Surveillance 
System.
Univariable and multivariable analyses were based on multilevel logistic regression models corrected for clustering within countries using 
an unstructured covariance matrix. TB cases with available information for all predicting factors were included in the multivariable analysis 
(n = 5,759/7,578). Excluded cases have a slightly higher treatment success (74.7% vs 73.8%; p value = 0.46).
Data source: TESSy.
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Comparison of studies has been hampered by different 
definitions used for INH mono-resistance. While many 
studies retained all INH resistance profiles, provided 
that RIF resistance and therefore MDR TB was excluded 
[8,16], other studies required additional documented 
susceptibility for STR and EMB [23] or analysed INH 
mono-resistant and INH poly-resistant cases with addi-
tional resistance to STR or EMB separately [12]. To avoid 
misclassification, we have used the stricter definition 
requiring documented DST results for INH, RIF, STR and 
EMB for all cases. However, while gaining specificity in 
the definition of INH mono-resistance, this approach 
has resulted in the loss of a large number of cases 
for which these susceptibility testing results were not 
available, with considerable differences in the percent-
ages of cases that could be included by country.
The finding that EU/EEA countries have different pro-
portions of patients with INH mono-resistant TB still 
under treatment at 12 months might be a surveillance 
artefact related to variation in reporting procedures or 
the result of the use of different treatment regimens 
with different durations, reflecting the current lack of 
an agreed standard regimen for the treatment of INH 
mono-resistant TB cases [18,25,26]. As the 12-month 
outcome therefore did not seem to be the most ade-
quate endpoint for analysis of the treatment outcome 
of INH mono-resistant TB, we chose a composite out-
come for this study using the final documented out-
come irrespective of the time to reporting (12 months, 
24 months or 36 months after the start of treatment).
The factors found to be associated with a higher risk of 
unsuccessful treatment outcome in INH mono-resistant 
TB in this study–higher age, male sex, positive micros-
copy, positive HIV status–have been described before 
as associated with unsuccessful TB treatment outcome 
independent of drug resistance status [27,28]. Prior 
TB treatment has also been reported as a risk factor 
for unsuccessful outcome in patients with INH mono-
resistant TB [29]. In our study, these factors influenced 
TB treatment outcome regardless of the presence or 
absence of INH mono-resistance, indicating that they 
are not specific to INH mono-resistant TB, but rather 
are associated with lower TB treatment success in 
general.
The strengths of our study are the inclusion of a large 
number of cases and the application of a multilevel 
model to correct for TB clustering. This allowed to 
control for possible selection bias related to reporting 
countries and for unobserved heterogeneity between 
countries, thereby enhancing the generalisability of our 
findings. However, there are also several limitations 
to our study, mainly related to the use of surveillance 
data collected with the aim to inform TB programme 
management and not to evaluate clinical outcomes. As 
a result, data on the severity of TB disease, underlying 
diseases and treatment regimens were not available.
In addition, information on DST for PZA is not avail-
able in the TESSy data. In a sensitivity analysis using 
German notification data (40,063 TB cases, of which 
1,310 were INH mono-resistant) that include informa-
tion on DST for PZA, cases resistant to PZA were more 
frequent among INH mono-resistant TB compared with 
otherwise fully susceptible TB cases (5.4% vs 1.8%; 
p < 0.01). However, no impact of the PZA resistance sta-
tus on the relationship between INH mono-resistant 
TB and treatment success was observed (adjusted 
OR: 0.8; 95% CI: 0.6–1.4; p = 0.77). Another limitation 
related to DST is that no information is available on the 
level of INH-resistance and the type of INH resistance 
mutations involved, which have been shown to influ-
ence treatment outcome [30].
Lastly, our study included data from only 24 of 31 
EU/EEA countries; cases from seven countries were 
excluded due to lack of reporting treatment outcome 
or case-based susceptibility data (Table 1). Therefore, 
our data pertain only to these 24 EU/EEA countries 
and cannot be generalised to the whole EU/EEA with-
out caution. Of note, 80.7% of reported cases had to 
be excluded due to missing information. As systematic 
reasons for lack of reporting within the 24 countries 
with included cases are not known, it is not possible 
for us to hypothesise how this might have affected our 
findings.
In conclusion, this study shows that treatment of 
patients with INH mono-resistant TB under routine pro-
gramme conditions leads to lower treatment success 
compared with fully susceptible TB. The association of 
INH mono-resistance with negative treatment outcome 
highlights the need to pay increased attention to the 
timely identification and management of these cases 
to ensure treatment success for individual patients, as 
well as to reduce the risk for further resistance devel-
opment on a population level.
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